2
|
Pang J, Xu H, Wang X, Chen X, Li Q, Liu Q, You Y, Zhang H, Xu Z, Zhao Y, Zhang Y, Yang Y, Ling W. Resveratrol enhances trans-intestinal cholesterol excretion through selective activation of intestinal liver X receptor alpha. Biochem Pharmacol 2021; 186:114481. [PMID: 33631191 DOI: 10.1016/j.bcp.2021.114481] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2020] [Revised: 01/14/2021] [Accepted: 02/16/2021] [Indexed: 12/20/2022]
Abstract
Resveratrol (RSV) is a dietary polyphenol with well-documented cardio-protective activity, but its effects on blood cholesterol levels remain to be established. Due to its poor bioavailability, tissue accumulation of RSV is extremely low except for that in the small intestine. In the present study, we aimed to investigate the dose-dependent effects of RSV on blood cholesterol levels and the involvement of small intestine in the cholesterol-lowering impacts of RSV. Mice were administrated with RSV at various doses with high-fat diet (HFD) or high-fat and high-cholesterol diet (HCD) for 12 weeks. The fecal neutral sterol contents were analyzed, and intestinal perfusion test was performed. An enteric barrier model using Caco-2 cells was established. We observed that RSV reduced blood cholesterol levels in a dose-dependent manner in mice fed with HFD or HCD. Further investigation revealed that RSV administration increased the bile acid pool size but did not affect cholesterol consumption or de novo cholesterol synthesis. Interestingly, RSV promoted trans-intestinal cholesterol excretion (TICE) by 2-fold in the intestinal perfusion test. In addition, RSV upregulated the expressions of ATP-binding cassette sub-family G member 5 or 8 (Abcg5/8) and ATP-binding cassette sub-family B member 1a or 1b (Abcb1a/b) by up to 8 times in the duodenum mucosa but not in the liver. RSV also significantly downregulated the expression of intestinal Niemann-Pick C1-Like 1 (Npc1l1). Knock-down of liver X receptor alpha (LXRα) but not Sirt1 by siRNA significantly blocked RSV-induced cholesterol excretion in Caco-2 cells. In conclusion, RSV could decrease circulating cholesterol levels through enhancing TICE and limiting cholesterol absorption via selective activation of intestinal LXRα.
Collapse
Affiliation(s)
- Juan Pang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Huihui Xu
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Xu Wang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Xu Chen
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Qing Li
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Qiannan Liu
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Yiran You
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Hanyue Zhang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Zhongliang Xu
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Yimin Zhao
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Yinghui Zhang
- School of Food Science and Engineering, Foshan University, Foshan 528225, PR China
| | - Yan Yang
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China
| | - Wenhua Ling
- Department of Nutrition, School of Public Health, Sun Yat-sen University, Guangzhou 510080, PR China; Guangdong Provincial Key Laboratory of Food, Nutrition and Health, Guangzhou 510080, PR China.
| |
Collapse
|
7
|
Chen Y, Duan Y, Yang X, Sun L, Liu M, Wang Q, Ma X, Zhang W, Li X, Hu W, Miao RQ, Xiang R, Hajjar DP, Han J. Inhibition of ERK1/2 and activation of LXR synergistically reduce atherosclerotic lesions in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 2015; 35:948-59. [PMID: 25810299 DOI: 10.1161/atvbaha.114.305116] [Citation(s) in RCA: 82] [Impact Index Per Article: 9.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
OBJECTIVE Activation of liver X receptor (LXR) inhibits atherosclerosis but induces hypertriglyceridemia. In vitro, it has been shown that mitogen-activated protein kinase kinase 1/2 (MEK1/2) inhibitor synergizes LXR ligand-induced macrophage ABCA1 expression and cholesterol efflux. In this study, we determined whether MEK1/2 (U0126) and LXR ligand (T0901317) can have a synergistic effect on the reduction of atherosclerosis while eliminating LXR ligand-induced fatty livers and hypertriglyceridemia. We also set out to identify the cellular mechanisms of the actions. APPROACH AND RESULTS Wild-type mice were used to determine the effect of U0126 on a high-fat diet or high-fat diet plus T0901317-induced transient dyslipidemia and liver injury. ApoE deficient (apoE(-/-)) mice or mice with advanced lesions were used to determine the effect of the combination of T0901317 and U0126 on atherosclerosis and hypertriglyceridemia. We found that U0126 protected animals against T0901317-induced transient or long-term hepatic lipid accumulation, liver injury, and hypertriglyceridemia. Meanwhile, the combination of T0901317 and U0126 inhibited the development of atherosclerosis in a synergistic manner and reduced advanced lesions. Mechanistically, in addition to synergistic induction of macrophage ABCA1 expression, the combination of U0126 and T0901317 maintained arterial wall integrity, inhibited macrophage accumulation in aortas and formation of macrophages/foam cells, and activated reverse cholesterol transport. The inhibition of T0901317-induced lipid accumulation by the combined U0126 might be attributed to inactivation of lipogenesis and activation of lipolysis/fatty acid oxidation pathways. CONCLUSIONS Our study suggests that the combination of mitogen-activated protein kinase kinase 1/2 inhibitor and LXR ligand can function as a novel therapy to synergistically reduce atherosclerosis while eliminating LXR-induced deleterious effects.
Collapse
Affiliation(s)
- Yuanli Chen
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Yajun Duan
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Xiaoxiao Yang
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Lei Sun
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Mengyang Liu
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Qixue Wang
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Xingzhe Ma
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Wenwen Zhang
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Xiaoju Li
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Wenquan Hu
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Robert Q Miao
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Rong Xiang
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - David P Hajjar
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.)
| | - Jihong Han
- From the State Key Laboratory of Medicinal Chemical Biology (Y.C., Y.D., J.H.), Collaborative Innovation Center of Biotherapy (Y.C., Y.D., R.X., J.H.), College of Life Sciences (Y.D., X.Y., L.S., M.L., Q.W., X.M., W.Z., X.L., J.H.), Nankai University, Tianjin, China; Department of Surgery, Medical College of Wisconsin, Milwaukee (W.H., R.Q.M.); and Department of Pathology, Weill Medical College of Cornell University, New York, NY (D.P.H.).
| |
Collapse
|